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Abstract
 
The mitogen-activated protein (MAP) kinase p38 is a key component of stress response path-
ways and the target of cytokine-suppressing antiinflammatory drugs (CSAIDs). A genetic ap-
 
proach was employed to inactivate the gene encoding one p38 isoform, p38
 
a
 
. Mice null for
 
the p38
 
a
 
 allele die during embryonic development. p38
 
a
 
1
 
/
 
2
 
 embryonic stem (ES) cells grown
in the presence of high neomycin concentrations demonstrated conversion of the wild-type al-
lele to a targeted allele. p38
 
a
 
2
 
/
 
2
 
 ES cells lacked p38
 
a
 
 protein and failed to activate MAP ki-
nase–activated protein (MAPKAP) kinase 2 in response to chemical stress inducers. In contrast,
p38
 
a
 
1
 
/
 
1
 
 ES cells and primary embryonic fibroblasts responded to stress stimuli and phosphory-
lated p38
 
a
 
,
 
 
 
and activated MAPKAP kinase 2. After in vitro differentiation, both wild-type and
p38
 
a
 
2
 
/
 
2
 
 ES cells yielded cells that expressed the interleukin 1 receptor (IL-1R). p38
 
a
 
1
 
/
 
1 
 
but
not p38
 
a
 
2
 
/
 
2 
 
IL-1R–positive cells responded to IL-1 activation to produce IL-6. Comparison
 
of chemical-induced apoptosis processes revealed no significant difference between the p38
 
a
 
1
 
/
 
1
 
and p38
 
a
 
2
 
/
 
2
 
 ES cells. Therefore, these studies demonstrate that p38
 
a
 
 is a major upstream acti-
vator of MAPKAP kinase 2 and a key component of the IL-1 signaling pathway. However,
p38
 
a
 
 does not serve an indispensable role in apoptosis.
Key words: inﬂammation • cytokines • mitogen-activated protein kinase • signaling • 
cytokine-suppressing antiinﬂammatory drug
 
Introduction 
 
After binding of the inflammatory cytokines IL-1 and TNF-
 
a
 
to their specific receptors on target cells, complex kinase-
 
mediated signaling cascades are initiated that lead to specific
changes in transcriptional and translational activities (1, 2).
Many of these same signaling pathways can be engaged by
chemical stress stimuli such as sodium arsenite or anisomy-
 
cin (3, 4), by UV irradiation, (5), and by LPS (6). Several
 
members of the family of mitogen-activated protein (MAP)
 
1
 
kinases are components of the stress response, including p38
 
and c-Jun NH
 
2
 
-terminal protein kinases (7, 8). These MAP
kinases regulate activity of key transcription factors including
ATF2, Elk, CHOP, MEF2C, and CREB (7, 9–12); this reg-
ulation is achieved, in part, by control of downstream kinases
such as MAP kinase–activating protein (MAPKAP) kinase 2
and 3 and p38-regulated/activated protein kinase (PRAK;
13–15). Stress-activated MAP kinases, therefore, serve as key
coordinators and/or regulators of a cell’s stress responsiveness.
p38 MAP kinase was first identified as an LPS-inducible
activity in murine peritoneal macrophages (6). Like other
members of the MAP kinase superfamily, p38 phosphory-
lates its substrates on serine/threonine residues, and itself re-
quires dual phosphorylation on both a threonine and ty-
rosine residue for activity (16). Several upstream MAP
kinase kinases (MKKs) have been reported to phosphorylate
p38 in vitro, including MKK3, MKK4, and MKK6 (17,
18). Four human p38 isoforms have been identified (
 
a
 
, 
 
b
 
,
 
g
 
, and 
 
d
 
), each containing the conserved dual phosphoryla-
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Abbreviations used in this paper:
 
 CSAID, cytokine-suppressing antiin-
flammatory drug; ES, embryonic stem; IC
 
50
 
, half-maximal inhibitory
concentration; MAP, mitogen-activated protein; MAPKAP, MAP ki-
nase–activated protein; MKK, MAP kinase kinase; NF, nuclear factor;
PARP, poly(ADP) ribose polymerase; PEF, primary embryonic fibro-
blast; RT, reverse transcription; SCML, recombinant murine leukemia
inhibitory factor. 
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tion sequence threonine-glycine-tyrosine (19–25). The dif-
ferent isoforms display distinct expression patterns (23, 26),
and data suggesting isoform-specific activities have been re-
ported (27). However, the precise biochemical function that
each isoform serves in vivo remains unclear.
Studies aimed at identification of the function of p38
were aided by realization that a novel class of cytokine-sup-
pressing antiinflammatory drugs (CSAIDs) achieved their
activity in part via inhibition of this kinase (19). Both the 
 
a
 
and 
 
b
 
 forms of p38 are reported to be CSAID sensitive (19–
21); in contrast, p38
 
g
 
 and p38
 
d
 
 appear to be insensitive to
these agents (23–25). Moreover, a panel of 12 other kinases
was shown to be insensitive to CSAID inhibition (28), indi-
cating that these agents are selective kinase inhibitors; struc-
tural and site-directed mutagenesis studies have recently
provided a basis for this selectivity (29–32). Mechanism of
action studies have demonstrated that CSAIDs prevent IL-
1
 
b
 
 and TNF-
 
a
 
 production by LPS-stimulated monocytes
and/or macrophages by affecting a posttransciptional process
(33, 34). In addition, CSAIDs have been shown to inhibit
synthesis of a wide variety of IL-1– or TNF-inducible
polypeptides, including IL-6 by fibroblasts (35), cyclooxy-
genase-2 by monocytes (36), and IFN-
 
g
 
 by T cells (37). In
these systems, the CSAID effect is manifested, in part, as in-
hibition of target-gene transcription. Moreover, CSAIDs
can suppress nuclear factor (NF)-
 
k
 
B–dependent transcrip-
tional events (38). These agents do not inhibit NF-
 
k
 
B acti-
vation per se, but may block activation of accessory factors
necessary for NF-
 
k
 
B–dependent transcription. Finally,
CSAIDs
 
 
 
are reported to alter apoptosis, in some cases pro-
moting (39) and in others inhibiting (40), and to impair
posttranslational processing of IL-1
 
b
 
 (41). Whether all re-
ported CSAID effects are attributable to p38 inhibition, and
to what extent the various p38 isoforms participate in sepa-
rate biological processes, are important issues that remain to
be clarified. Recent studies demonstrating that CSAIDs can
also block cyclooxygenase activity (42) and increase Raf-1
activity (43) highlight the potential for CSAID-mediated
cellular effects occurring independently of p38.
 
To better understand the biological function of p38
 
a
 
, a
genetic approach was used to inactivate the gene encoding
this kinase by homologous recombination in embryonic
stem (ES) cells. Inbred DBA/1 lacJ mice that are p38
 
a
 
 null
die during early embryonic development. However, growth
of p38
 
a
 
1
 
/
 
2
 
 ES cells in the presence of increased concentra-
tions of neomycin led to isolation of a p38
 
a
 
2
 
/
 
2
 
 ES cell line.
These enzyme-deficient cells were used to investigate the
role of p38
 
a
 
 in stress activation pathways. Results derived
from this analysis confirm that p38
 
a
 
 is a major upstream ac-
tivator of MAPKAP kinase 2 and an important component
of the IL-1 signaling pathway. On the other hand, the re-
sults provide no indication that p38
 
a
 
 is a necessary compo-
nent of the chemical-induced apoptotic response mecha-
nism of ES cells. Therefore, these studies help to clarify the
role of p38
 
a
 
 in stress response pathways.
 
Materials and Methods
 
Construction of the p38
 
a
 
 Targeting Vector. 
 
A 759-bp murine p38
 
a
 
partial genomic PCR fragment was used as a probe to identify ge-
nomic clones from a DBA/1 lacJ genomic phage library (Strat-
agene). The p38
 
a
 
 targeting vector (Fig. 1) was constructed by
cloning 5.5 kb of 5
 
9
 
 homology and 3.5 kb of 3
 
9
 
 homology into a
pJNS2 (PGK-NEO/PGK-Tk) backbone vector. The targeting
vector replaced 
 
z
 
8–10 kb of genomic locus, containing the TGY
dual phosphorylation site required for kinase activation, with
PGK-NEO.
 
Generation of p38
 
a
 
-deficient ES Cells. 
 
DBA/252 ES cells (44,
45) were cultured on primary embryonic fibroblasts (PEFs) in
DMEM containing high glucose, 15% heat-inactivated fetal bo-
vine serum, 0.2 mM 
 
l
 
-glutamine, 0.1 mM 2-ME, 0.1 mM MEM
nonessential amino acids, penicillin-streptomycin, and 400 U/ml
recombinant murine leukemia inhibitory factor (SCML). The
p38
 
a
 
 targeting vector (25 
 
m
 
g) was electroporated at 1.0 
 
3
 
 10
 
8
 
 ES
cells/ml (0.4 ml total volume), and the electroporation was
achieved with a BTX Electrocell Manipulator 600 (200 V, 50 
 
m
 
F,
360 
 
V
 
). Cells were subsequently subjected to positive/negative se-
lection with 200 
 
m
 
g/ml G418 (geneticin; Life Technologies) and
2 
 
m
 
M gancyclovir (Syntex Laboratories) as described (46). Gene
targeting by homologous recombination was determined by
Figure 1. Scheme employed
to achieve homologous recom-
bination of the murine p38a lo-
cus. Approximately 8–10 kb of
endogenous genomic sequence,
including regions necessary for
p38a enzymatic activity, was re-
placed by the neomycin gene;
this creates a deletion from phe-
nylalanine 129 to aspartic acid
283 within the native protein.
Hybridization of ES cell DNA
with an external probe identified
a predicted RFLP of 6.5 kb, cre-
ated as a result of the introduc-
tion of a novel EcoRI restriction
site in the targeting vector. 
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Southern analysis using a 5
 
9
 
 361-bp external PCR probe in con-
junction with EcoRI-digested ES cell DNA. As depicted in Fig. 1,
the endogenous wild-type allele yielded a band hybridizing at 7.7
kb, whereas the targeted allele revealed a predicted RFLP at 6.5
kb due to the introduction of a novel EcoRI site from the p38
 
a
 
targeting vector. The parental heterozygous p38
 
a
 
 ES cell line was
subsequently cultured in vitro in SCML supplemented with 2 mg/
ml G418, according to published methods, to generate p38
 
a
 
2
 
/
 
2
 
cells (47).
 
Differentiation of ES Cells. 
 
Cultures of wild-type and p38
 
a
 
2
 
/
 
2
 
ES cells were maintained in the absence of SCML for 16 d to pro-
mote formation of embryoid bodies. These structures were disso-
ciated by trypsin digestion to generate single cell suspensions, and
the cells were seeded into IMDM containing 4.5 
 
3 
 
10
 
2
 
4
 
 M
monothiolglycerol, 15% fetal bovine serum, 2 mM glutamine, 1%
methylcellulose, 0.1 ng/ml IL-3, 10 ng/ml IL-6, and 3 ng/ml
GM-CSF to promote differentiation to a myeloid-like phenotype.
Recombinant murine IL-3, IL-6, and GM-CSF were obtained
from Life Technologies. The cultures were maintained for 12 d,
then were harvested and stained with PE-labeled anti–murine type
1 IL-1R antibody (PharMingen) or with a control PE-labeled IgG
(Caltag). The antibody-stained cells were analyzed by FACS
 
®
 
, and
IL-1R–positive cells were collected.
 
Generation of PEFs. 
 
PEFs were isolated from day 12 DBA/1
lacJ embryos by established methods (48). In contrast, p38
 
a
 
2
 
/
 
2
 
embryos were not viable at 12 d postcoitum. Therefore, to derive
p38
 
a
 
2
 
/
 
2
 
 PEF cell lines, attempts were made to rescue the early
embryonic lethality in chimeric embryos. p38
 
a
 
2
 
/
 
2
 
 ES cells were
microinjected into day 2.5 C57BL/6 blastocysts, and embryos
were recovered at 12 d after transfer to pseudopregnant females.
To isolate the p38
 
a
 
2
 
/
 
2
 
 PEFs from the pooled chimeric cell popu-
lation, the primary cell cultures were maintained in the presence
of 200 
 
mg/ml G418. The G418 selection killed all C57BL/6 wild-
type cells, and the p38a2/2 cells survived selection because of the
insertion of the neomycin resistance gene in the original targeting
vector. However, attempts to expand this p38a2/2 PEF population
failed within 24 h of passage of original selected cultures.
Reverse Transcription PCR Analysis of p38 Kinase Expression.
Reverse transcription (RT)-PCR was performed on 1 mg of total
ES cell or liver RNA in a 20-ml reaction mixture containing 13
PCR buffer (Life Technologies) supplemented with 500 mM each
dNTP, 2.5 mM MgCl2, 0.01 M DTT, and 200 U SuperScript II
reverse transcriptase (Life Technologies). The RT reaction was
carried out for 1 h at 428C, followed by denaturation at 708C for
15 min. Aliquots (2 ml) of each RT reaction mixture were then
amplified in a 50-ml reaction volume containing 13 PCR buffer,
1.4 mM MgCl2, 200 mM each dNTP, 0.4 mM each primer, and
1 U Taq polymerase (Boehringer Mannheim). PCR cycling con-
ditions were 30 cycles at 948C for 30 s, 558C for 30 s, and 728C
for 1 min. In addition to using liver as a positive tissue control for
p38 isoform expression, amplification of the housekeeping gene
b-actin was carried out as a positive control for the RT reaction.
RT-PCR was also performed on all RNA samples in the absence
of the reverse transcriptase to eliminate the possibility that contam-
inating DNA contributed to the PCR amplification; no transcripts
corresponding to the p38 species were detected (data not shown).
Primers employed in the RT-PCR analysis consisted of the follow-
ing: p38a, 59-GATTCTGGATTTTGGGCTGGCTCG-39 and
59-ATCTTCTCCAGTAGGTCGACAGCC-39; p38b, 59-ATC-
CATCGAGGATTTCAGCG-39 and 59-CCTCCATGATTCG-
CTTCAGC-39; p38d, 59-ATTCAGCGAGGATAAGGTCC-39
and 59-AGTCACTTTCAGGATCTGGG-39; p38g, 59-ACTTC-
ACAGACTTCTACCTGG-39 and 59-CAAAGTATGGATGGG-
TTAACG-39; b-actin, 59-GTGGGCCGCTCTAGGCACCAA-39
and 59-CTCTTTGATGTCACGCACGATTTC-39. To ensure
that no other murine genes would cross-hybridize to these specific
primer nucleotide sequences, they were prescreened against the
BLASTN sequence similarity database (available at newblast@
ncbi.nlm.nih.gov). PCR products were size separated by electro-
phoresis on a 2% agarose gel, and were visualized by ethidium
bromide staining.
IL-6 ELISA.  Wild-type and p38a2/2 ES cells and PEFs
were cultured overnight in 1 ml SCML containing no effector,
human TNF-a (10–20 ng/ml), or human IL-1b (10–20 ng/ml);
the recombinant cytokines were obtained from Upstate Biotech-
nology. Where indicated, the CSAID SB-203,580 (Calbiochem)
was added to the culture medium. Media were harvested, clarified
by centrifugation, and analyzed in an IL-6 ELISA (Endogen). The
assay was performed as instructed by the manufacturer.
Western Blot Analysis. Cell monolayers (3.5-cm dishes) were
washed with PBS, after which 0.1 ml of 23 concentrated Laem-
mli sample buffer (49) was added, and cells were dislodged by
scraping. Cell lysates were transferred to Eppendorf centrifuge
tubes and subjected to several bursts of a microtip sonicator to re-
duce viscosity. These same samples were subsequently boiled for
3 min, and 20 ml of each extract was subjected to SDS-PAGE us-
ing 12% Novex minigels. When completed, gels were blotted
onto Trans-Blot transfer medium (0.45 mm nitrocellulose; Bio-
Rad Laboratories). The resulting blots were blocked by immersion
in TBST (10 mM Tris, pH 8, 150 mM NaCl, and 0.1% Tween-
20) containing 5% nonfat dry milk for 1 h at room temperature.
Blots were rinsed with TBST, then incubated overnight at 48C in
TBST containing 5% BSA and a 1:1,000 dilution of the appropri-
ate primary antibody. For detection of total and phosphorylated
p38, a rabbit polyclonal anti-p38 MAP kinase antibody (New En-
gland Biolabs) and a rabbit polyclonal antiphospho-p38 MAP ki-
nase antibody (New England Biolabs) were used. After treatment
with the primary antibodies, blots were washed with three
changes of TBST, then immersed in TBST containing 5% nonfat
dry milk with a 1:2,000 dilution of horseradish peroxidase–conju-
gated goat anti–rabbit IgG. After a 60-min incubation, blots were
washed three times with TBST, then placed in LumiGlo™ (New
England Biolabs). Immune complexes were visualized by expo-
sure to X-ray film.
MAPKAP Kinase 2 Assay. ES cells were seeded (4 3 106
cells) into 6-well cluster dishes and maintained in SCML medium.
The growth medium was removed and replaced with 1 ml of me-
dium containing, where indicated, 50 ng/ml anisomycin or 0.5
mM sodium arsenite, and the cultures were incubated for 15 min
at 378C. Monolayers were then rinsed with PBS and treated with
1 ml PBS containing 1% Triton X-100 to promote cell lysis. After
a 10-min incubation on ice, extracts were clarified by centrifuga-
tion for 20 min at 50,000 rpm in a TLA-100.3 ultracentrifuge ro-
tor (Beckman Instruments). MAPKAP kinase 2 activity within the
resulting supernatants was determined using a peptide-based sub-
strate obtained from Upstate Biotechnology. In brief, 5 mg sheep
anti–rabbit MAPKAP kinase 2 antibody was incubated with 1 ml
of a 5% suspension of protein G–sepharose in PBS containing 1%
Triton X-100 and Complete® protease inhibitor (Boehringer
Mannheim). After a 60-min incubation, beads were recovered by
centrifugation and washed twice with 50 mM Tris, pH 7.5, 1 mM
EDTA, 1 mM EGTA, 0.5 mM sodium orthovanadate, 0.1%
b-mercaptoethanol, 1% Triton X-100, 5 mM sodium pyrophos-
phate, 10 mM sodium glycerophosphate, 0.1 mM PMSF, 1 ug/ml
leupeptin, 1 ug/ml pepstatin, and 50 mM sodium fluoride (buffer
A). Individual bead pellets were suspended in 1 ml of the clarified862 Stress Response of p38a Kinase–deficient Embryonic Stem Cells
cell extracts, incubated at 48C for 2 h with gentle rocking, and
collected by centrifugation. The beads were washed once with 0.5
ml of buffer A containing 0.5 M sodium chloride, once with 0.5
ml of buffer A, and once with 0.1 ml of 20 mM 4-morpholine
propanesulfonic acid, pH 7.2, containing 25 mM b-glycerophos-
phate, 5 mM EGTA, 1 mM sodium orthovanadate, and 1 mM
DTT (kinase buffer). Final bead pellets were suspended in 40 ml of
an assay mixture composed of kinase buffer supplemented with
125 mM ATP, 10 mM MgCl2, 100 mM MAPKAP kinase 2 sub-
strate peptide, and 250 mCi/ml [g-32P]ATP (DuPont). Reaction
mixtures were incubated at 308C for 30 min, after which 25 ml of
each was spotted onto individual p81 phosphocellulose squares
(Whatman). These filters were washed with four changes of 0.75%
phosphoric acid, once with acetone, then air dried and placed in 4 ml
of liquid scintillation fluid for radioactivity determination.
Animal Handling. All procedures involving mice were ap-
proved by the Institutional Animal Care and Use Committee at
Pfizer Central Research.
Results
Embryonic Lethality Associated with p38a Deficiency.  Mouse
ES cells in which the p38a gene was disrupted by homolo-
gous recombination were generated using the scheme shown
in Fig. 1. The targeted ES cells successfully contributed to
the germline of resulting chimeric mice. F1 generation 1/2
animals were grossly normal, fertile, and displayed no dis-
cernible phenotype. Contrary to expected Mendelian seg-
regation, offspring from the F2 generation demonstrated
the 1/1 and 1/2 genotypes at frequencies of 38% (n 5
21) and 62% (n 5 34), respectively. No p38a2/2 animals
were obtained, indicating that the p38a-deficient pheno-
type is an embryonic lethal. We conclude that p38a must
serve an essential role in murine development.
Generation of p38a2/2 ES Cells.  ES cells heterozygous
for the p38a MAP kinase locus were subjected to growth in
the presence of 2 mg/ml G418 to increase selective pressure
for neomycin resistance and convert the wild-type allele to a
targeted allele (47). After 23 d of selection, 64 independent
clonal isolates were recovered. After Southern blot analysis,
17 (25%) of these clones were shown to be null for the p38a
allele (Fig. 2). One of the p38a2/2 cell lines was expanded
and used in the biochemical analysis described below.
To assess whether ES cells express all known p38 family
members, RT-PCR was performed on total RNA prepared
from wild-type (1/1) DBA/252 ES cells and from two cell
lines that demonstrated either heterozygosity (1/2) or the
complete absence (2/2) of the p38a allele by Southern
blotting. This analysis indicated that wild-type ES cells ex-
press mRNA for p38a, b, g, and d (Fig. 3). Likewise, total
RNA prepared from liver of an adult DBA wild-type mouse
contained transcripts encoding each of the four p38 kinases,
although the b species appeared to be in low abundance
(Fig. 3). In contrast, total RNA isolated from p38a2/2 ES
cells showed no evidence of the p38a transcript, but these
cells maintained expression of p38b,  g, and d (Fig. 3).
p38a1/2 ES cells, on the other hand, yielded RNA tran-
scripts corresponding to each of the four p38 kinases. Within
the limits of the RT-PCR approach, no obvious change in
the relative expression levels of the p38b, g, and d species
was observed between the 1/1 and 2/2 ES cell lines.
Comparison of the IL-1 Responsiveness of PEF and ES Cells.
Inflammatory cytokines such as IL-1 can promote IL-6 pro-
duction by cell types that express the appropriate signaling
receptors (35, 36). To determine whether inflammatory cy-
tokine signaling cascades were operative in PEF and ES
cells, individual cultures were treated with IL-1 or TNF-a,
after which IL-6 released into the medium was determined
by ELISA. In the absence of a cytokine effector, PEFs iso-
lated from wild-type embryos produced minimal quantities
of IL-6 (Fig. 4 A). However, in response to IL-1 stimula-
tion, these fibroblasts generated large quantities of extracel-
lular IL-6 (Fig. 4 A). Likewise, PEFs responded to TNF-a
and generated IL-6, but cytokine levels produced in re-
sponse to TNF-a were less than those elicited by an equiv-
alent concentration of IL-1 (Fig. 4 A). Attempts to isolate
p38a2/2 PEFs from day 12 chimeric embryos were unsuc-
cessful; fibroblast-like cells were recovered after G418 selec-
tion, but these did not survive during culture. Unstimulated
ES cells did not produce IL-6, and addition of IL-1 or
TNF-a to their medium did not result in an increase in IL-6
production (Fig. 4 A). This lack of responsiveness suggests
that DBA/1 lacJ ES cells lack signaling receptors for IL-1
and TNF, as has previously been noted for ES cells derived
from other mice strains (50).
IL-1–induced IL-6 production by PEFs appeared to be
dependent on p38. Stimulation of these fibroblasts with IL-1
in the presence of the CSAID SB-203,580 inhibited pro-
duction of IL-6 in a dose-dependent manner (Fig. 4 B); a
Figure 2. Southern analysis of ES cell clones. EcoRI restriction en-
zyme–digested ES cell genomic DNA was electrophoresed, transferred to
nitrocellulose, and hybridized to the 59 external probe of the p38a locus.
(A) A blot showing wild-type (1/1) and the parental heterozygous (1/2)
ES cell clones. (B) A blot showing examples of G418-surviving ES cell
clones; this blot is representative of 64 surviving clones. The positions of
the wild-type (WT) and knockout (KO) alleles are indicated.
Figure 3. Expression of the four mu-
rine p38 isoforms and b-actin in wild-
type (1/1) ES cells, wild-type liver
(liv), p38a-deficient (2/2) ES cells,
and p38a heterozygous (1/2) ES
cells. The observed RT-PCR product
sizes agreed with the predicted values
and are as follows: p38a, 368 bp; p38b,
430 bp; p38d, 354 bp; p38g, 632 bp;
and b-actin, 540 bp.863 Allen et al.
half-maximal inhibitory concentration (IC50) of 3 mM was
estimated for the inhibitory effect (Fig. 4 B).
ES Cells and PEFs Respond to Stress Stimuli and Activate
p38a.  In addition to cytokines, chemical stress stimuli
can activate p38 (3, 4). Therefore, ES cells and PEFs were
treated with two agents previously demonstrated to activate
p38, anisomycin and sodium arsenite. To assess p38 activa-
tion, cell lysates were prepared and analyzed by Western
blotting both for total p38a content and the presence of
phosphorylated p38a. The absolute amount of p38a recov-
ered in extracts of ES cells and PEFs did not change in re-
sponse to the various activation stimuli (Fig. 5). In contrast,
quantities of phosphorylated p38a were not equivalent, and
were dependent on the activation stimulus (Fig. 5). ES cells
that were pretreated with anisomycin (50 ng/ml) or sodium
arsenite (0.5 mM) yielded phosphorylated p38a (Fig. 5).
On the other hand, stimulation of the ES cells with IL-1 or
TNF-a did not promote p38a phosphorylation (Fig. 5);
this lack of cytokine responsiveness again suggests that ES
cells do not possess the corresponding cytokine receptors.
In addition, LPS did not promote phosphorylation of ES
cell p38a. Therefore, ES cells possess p38a, and this en-
zyme can be activated by chemical inducers of stress such as
anisomycin and sodium arsenite, but not by inflammatory
cytokines (IL-1 or TNF-a) or by LPS.
PEFs also responded to the chemical stress stimuli to gen-
erate phosphorylated p38a. Nonstimulated PEFs possessed a
low level of phosphorylated p38a, and treatment with either
anisomycin or sodium arsenite elevated levels of the phos-
phorylated enzyme (Fig. 5). Levels of total p38a in the fibro-
blasts were not affected by the various stimuli (Fig. 5). In ad-
dition, PEFs stimulated with IL-1, and to a lesser degree
with TNF-a, yielded elevated levels of phosphorylated p38a
(Fig. 5); similarly, LPS treatment yielded elevated levels of
the phosphorylated enzyme. Therefore, PEFs differ from ES
cells in that they generate phosphorylated p38a in response
to chemical stress inducers and selective cytokine activators.
p38a-deficient ES cells were subjected to a similar analy-
sis. Extracts derived from anisomycin-treated p38a1/2 and
p38a1/1 ES cells contained p38a, and this enzyme was
phosphorylated in response to the chemical stress inducer
(Fig. 6). In contrast, extracts derived from aniosomycin-
treated p38a2/2 ES cells did not contain p38a or the phos-
phorylated p38a polypeptide species (Fig. 6).
Figure 4. PEFs, but not ES
cells, produce IL-6 in response
to inflammatory cytokine stim-
uli. (A) Cultures of PEFs or
wild-type ES cells were incu-
bated overnight in medium con-
taining no effector (None) or 10
ng/ml of IL-1b or TNF-a, after
which IL-6 released to the me-
dium was measured by ELISA.
The ELISA signal is indicated as
a function of treatment (average
of duplicate determinations).
This experiment was repeated
twice with comparable results.
(B) PEFs were stimulated over-
night with 10 ng/ml of IL-1 in
the absence or presence of the indicated concentration of SB-203,580. IL-6 released to the medium was determined by ELISA (average of duplicate de-
terminations). These data are representative of three separate experiments.
Figure 5. Identification of stimuli that
promote p38a phosphorylation in PEFs
and wild-type ES cells. Cells were stim-
ulated for 15 min in the presence of the
indicated effector, and then were solubi-
lized by detergent extraction. Equal
quantities of these extracts were frac-
tionated on two separate gels, and the
separated polypeptides were transferred
to nitrocellulose for Western blot analy-
sis. One blot was treated with an anti-
body that detects total p38a (p38), and
the other with an antibody that detects
phosphorylated p38a (phospho-p38).
Extracts derived from control and aniso-
mycin-treated C6 cells are included as
standards. Identity of the slightly slower
migrating antigenic species detected in
the ES cell extracts with the phospho-
specific antibody (arrow) is unknown.864 Stress Response of p38a Kinase–deficient Embryonic Stem Cells
MAPKAP Kinase 2 Activation Is Dependent on p38a.
Previous studies established that MAPKAP kinase 2 is a sub-
strate of p38a (4). However, the extent to which other ki-
nases may participate in vivo in the activation of MAPKAP
kinase 2 remains unclear. To determine whether stress acti-
vation of MAPKAP kinase 2 in ES cells is p38a dependent,
1/1 and 2/2 ES cells were stimulated with anisomycin
or sodium arsenite, and cell extracts were isolated. MAP-
KAP kinase 2 was subsequently recovered by immunopre-
cipitation, and kinase activity associated with the immuno-
precipitates was assessed. In the absence of a stimulus, both
p38a1/1 and p38a2/2 ES cells yielded low levels of immu-
noprecipitable MAPKAP kinase 2 activity (Fig. 7 A). Pre-
treatment with anisomycin or sodium arsenite stimulated
MAPKAP kinase 2 activity in extracts derived from p381/1
ES cells. Sodium arsenite–stimulated cells achieved a greater
level of activity than did the anisomycin-treated cells (Fig. 7
A). In contrast to this large increase in MAPKAP kinase 2
activity, p38a2/2 cells stimulated with anisomycin or so-
dium arsenite demonstrated greatly attenuated responses
(Fig. 7 A). No significant increase in MAPKAP kinase 2 ac-
tivity was observed when p38a2/2 cells were stimulated
with anisomycin, and sodium arsenite treatment yielded only
a fourfold increase in activity (Fig. 7 A). Sodium arsenite
treatment of p38a1/1 ES cells, on the other hand, yielded
.800-fold increase in MAPKAP kinase 2 activity relative to
the nonstimulated level (Fig. 7 A).
Sodium arsenite–induced MAPKAP kinase 2 activation
was inhibited by the CSAID SB-203,580. p38a1/1 ES cells
treated with sodium arsenite in the presence of 2 mM SB-
203,580 yielded 67% less MAPKAP kinase 2 activity than
did their counterparts activated in the absence of the
CSAID (Fig. 7 B). Likewise, the modest increase in MAP-
KAP kinase 2 activity observed when p38a2/2 ES cells
were stimulated with sodium arsenite was inhibited by 63%
in the presence of SB-203,580 (Fig. 7 B). Therefore, ab-
sence of p38a greatly impaired the ability of stress stimuli to
promote MAPKAP kinase 2 activation, but a small CSAID-
sensitive component remained in the p38a-deficient cells.
ES Cells Differentiated In Vitro to IL-1R–positive Fibroblast-
like Cells Demonstrate an Impaired Response to IL-1 in the Ab-
sence of p38a.  ES cells can undergo differentiation-type
processes when maintained under appropriate culture con-
ditions (51). In an attempt to derive cells expressing IL-1R,
p38a1/1 and p38a2/2 ES cells were allowed to form em-
bryoid bodies. These structures then were dissociated, and
the resulting individual cells were cultured for an additional
12 d in the presence of a cytokine mixture composed of
IL-3, IL-6, and GM-CSF. The resulting cell populations
were separated by FACS® on the basis of binding of mu-
rine anti–IL-1R antibodies. The percentage of cells staining
positive for IL-1R was comparable in both the p38a1/1
and p38a2/2 cultures, representing 19 and 16%, respec-
tively (Fig. 8 A). Staining above a nonimmune IgG control
was used as a specificity control. Before the in vitro differ-
entiation process, neither ES cell population stained posi-
tive for type 1 IL-1R (data not shown).
FACS®-sorted IL-1R–positive cells were cultured in the
presence of IL-1. Cytokine stimulation of the IL-1R–posi-
Figure 6. Demonstration that p38a2/2 ES cells lack immunodetectable
p38a. Wild-type (ES1/1) and p38a-deficient ES cells were stimulated
with sodium arsenite for 15 min and then solubilized by detergent extrac-
tion. Duplicate samples of each extract were loaded onto separate gels and
processed for Western blotting. Antigen detected after staining these blots
with an antibody against total (p38) or one selective for phosphospecific
(phospho-p38) forms are indicated. Extracts of IL-1–stimulated PEFs and
C6 cells are included as standards. Arrow indicates the migration of p38a,
and the arrowhead marks the antigen detected by the phospho-specific
antiserum in the ES cell samples that is not p38 dependent.
Figure 7. MAPKAP kinase 2 activa-
tion in wild-type and p38a2/2 ES cells.
Cultures of p38a1/1 and p38a2/2 ES
cells were incubated with the indicated
effector for 15 min, after which the cells
were solubilized by detergent extrac-
tion, and MAPKAP kinase 2 was recov-
ered by immunoprecipitation. The re-
sulting immunoprecipitates were then
assayed for kinase activity using a pep-
tide substrate and [g-32P]ATP. Radioac-
tivity (in cpm) incorporated into the
peptide substrate is indicated as a func-
tion of treatment; a background (no en-
zyme control) was subtracted to correct
for non–peptide-associated radioactivity
sticking to the filter. This experiment
was repeated twice with comparable re-
sults. Each value is the average of dupli-
cate determinations.865 Allen et al.
tive p38a1/1 cells resulted in expression of IL-6 (Fig. 8 B);
in the absence of IL-1, little IL-6 was generated (Fig. 8 B).
Coincubation with SB-203,580 during the IL-1 activation
period led to a dose-dependent decrease in IL-6 production
(Fig. 8 B). The IC50 for this response was estimated to be
2 mM, a value consistent with the IC50 observed in PEFs
(Fig. 1). In contrast, cultures of IL-1R–positive p38a2/2 cells
generated much less IL-6 in response to IL-1 stimulation, and
this increase was not reduced by the CSAID (Fig. 8).
Absence of p38a Does Not Alter ES Cell Apoptosis.  p38a
has been implicated as an important regulator of apoptotic
processes (52, 53), and we considered the possibility that a
defect in apoptosis contributed to the embryonic lethality
observed with the knockout animals. To assess the apop-
totic responsiveness of the p38a1/1 and p38a2/2 ES cells,
they were initially treated with anti-Fas, a well-character-
ized inducer of apoptosis (53). However, DBA ES cells
failed to bind fluorescently labeled anti-Fas antibody (as de-
tected by FACS®; data not shown), negating use of the Fas-
induced apoptotic mechanism. Therefore, chemical stimuli
were used to promote apoptosis of p38a1/1 and p38a2/2
ES cells. Staurosporin induces apoptosis in many cell systems,
and this process is accompanied by caspase-dependent cleav-
age of the cytoplasmic protein poly(ADP) ribose polymerase
(PARP [54]). p38a1/1 ES cells treated overnight with in-
creasing concentrations of staurosporin demonstrated a dose-
dependent increase in levels of the 85-kD PARP cleavage
product as assessed by Western analysis (Fig. 9 A). Extracts
prepared from cells treated with concentrations of stauro-
sporin ,5 mM did not contain the 85-kD cleavage frag-
ment (Fig. 9 A). At these lower staurosporin concentrations,
wild-type cells yielded full-length 116-kD PARP and a
slightly faster migrating antigenic species; presence of this lat-
ter species was not staurosporin dependent. However, as the
concentration of staurosporin was increased to .10 mm, lev-
els of the 85-kD PARP cleavage product increased in the
p381/1 ES cell extracts (Fig. 9 A). Appearance of the PARP
cleavage fragment within extracts of p38a2/2 ES cells dem-
onstrated a similar dependence on staurosporin concentra-
tion (Fig. 9 A). No significant difference in the responsive-
ness of the two cell types was noted in multiple experiments.
Figure 8. IL-1–induced IL-6 production by in vitro–differentiated ES cells. Wild-type and p38a2/2 ES cells were subjected to in vitro differentiation.
(A) Cells recovered from each culture were stained with a PE-labeled control IgG or PE-labeled anti–IL-1R IgG, and the cell mixtures were analyzed by
FACS®. Cells were gated by autofluorescence, an indicator of size (x-axis), and by PE fluorescence intensity (y-axis). The percentage of cells demonstrat-
ing a PE fluorescence intensity above the background level is indicated in each panel. (B) IL-1R–positive cells recovered by sorting were plated into cul-
ture wells and stimulated with IL-1b (10 ng/ml) in the absence or presence of SB-203,580. After an overnight stimulation, media were harvested and as-
sayed for IL-6 by ELISA. The amount of IL-6 produced is indicated as a function of treatment. These results are representative of four separate
experiments. wt, wild-type.
Figure 9. Deletion of p38a does not inhibit ES cell apoptosis in re-
sponse to chemical stimuli. p38a1/1 and p38a2/2 ES cells were treated
with the indicated concentration of staurosporin (A) or adriamycin (B) for
16 h, and then were disaggregated with SDS sample buffer. Samples of
the resulting lysates were subjected to Western blot analysis with an anti-
PARP antibody. Regions of the blots corresponding to full-length
116-kD PARP and its 85-kD cleavage fragment are shown as a function
of the effector concentration.866 Stress Response of p38a Kinase–deficient Embryonic Stem Cells
Adriamycin was recently reported to induce caspase-
dependent apoptosis of murine ES cells (55), and sensitivity
to this agent was also characterized. Extracts prepared from
both p381/1 and p382/2 ES cells yielded the 85-kD PARP
cleavage fragment in response to adriamycin treatment (Fig.
9 B), and concentrations of this agent required to generate
the cleavage fragment again were similar between the two
cell lines (Fig. 9 B).
Apoptosis was also assessed by flow cytometry using the an-
nexin V/propidium iodide staining procedure (56). Adriamy-
cin concentrations between 0.05 and 4.5 mg/ml led to a dose-
dependent decrease in cell viability (Table I). Comparison of
the sensitivity of p38a1/1 and p38a2/2 ES cells revealed a
similar concentration dependence in the annexin V/propid-
ium iodide staining profiles (Table I). Moreover, addition of
10 mM SB-203,580 to the culture medium did not signifi-
cantly alter the percentages of viable cells detected in the adri-
amycin-treated p38a1/1 and p38a2/2 ES cell populations
(Table I).
Discussion
p38 is activated by a variety of extracellular stimuli, in-
cluding inflammatory cytokines such as IL-1 and TNF,
growth factors such as fibroblast growth factor (FGF) and
CSF, osmolarity changes, UV light, and chemical agents that
promote a stress response (7). The diverse nature of these
activators suggests that p38 serves as a point of convergence
for a variety of extracellular effectors. Based on this multi-
plicity of activators, it is perhaps not surprising that deletion
of p38a led to embryonic lethality. A similar fate has been
observed for mice engineered to lack other signaling kinases
including MKK4 (50, 57); function of these signaling ki-
nases must be essential to normal development. Several
CSAIDs recently were reported to inhibit FGF-induced
proliferation of Swiss 3T3 fibroblasts (58). Perhaps a p38a
dependence in a growth factor–induced proliferative re-
sponse contributes to the lethal phenotype of the p38a2/2
embyros, and to our inability to maintain p38a2/2 PEFs
isolated from chimeric embryos in culture. Since mice, like
humans, appear to express multiple p38 kinase family mem-
bers (59), the developmental arrest suggests that the different
enzymes do not perform redundant activities, at least during
embryonic development. Deletion of p38a also has been as-
sociated with murine embryonic lethality in a 129SvEv 3
C57BL/6 genetic background, where the arrest was attrib-
uted to a defect in placental development (60).
The four human p38 kinases display distinct expression
patterns (23, 24). By Northern blot analysis, transcripts for
38a, p38b, and p38d were found in many human tissues,
but the relative abundance of an individual species varied
widely from tissue to tissue (23). In contrast, p38g transcripts
were abundantly expressed only in skeletal muscle, with
minimal expression in most other tissues (23). Not only is
expression regulated, but also within the same cell type two
forms of the enzyme may demonstrate differential activation
requirements. For example, human macrophages express
both p38a and p38d, but p38a was activated to a greater ex-
tent than was p38d after LPS stimulation (26). This differen-
tial activation may be achieved through the use of distinct
upstream activators (20, 61, 62). For example, p38a was effi-
ciently activated by MKK3, MKK4, or MKK6 in transfected
COS-7 cells, whereas p38b was phosphorylated only by
MKK6 (20). Finally, forced activation of overexpressed
p38a and p38b was reported to promote cardiomyocyte ap-
optosis and hypertrophy, respectively, suggesting that the in-
dividual p38 kinases initiate separate cellular processes (27).
Generation of cells deficient in p38a allowed us to ex-
plore this enzyme’s role in several stress response pathways.
Chemical agents such as anisomycin and sodium arsenite
promote activation of p38 in a variety of cell types (3, 4).
Indeed, p38a1/1 ES cells and PEFs treated with these
agents demonstrated increased phosphorylation of p38a and
an increased level of MAPKAP kinase 2 activity. In contrast,
p38a-deficient ES cells failed to efficiently activate MAP-
KAP kinase 2 in response to anisomycin or sodium arsenite
exposure. Therefore, p38a appears to be a critical compo-
nent of the MAPKAP kinase 2 activation cascade in re-
sponse to chemical stress inducers. Interestingly, a small in-
crease in MAPKAP kinase 2 activity persisted after sodium
arsenite treatment of p38a2/2 ES cells and, as in wild-type
ES cells, this increase was blocked by SB-203,580. The
magnitude of the CSAID effect against the residual activity
was similar to that observed in wild-type cells. Since human
p38b, in contrast to the g and d isoforms, is CSAID sensi-
tive (20, 21, 23–25), perhaps the mouse equivalent is re-
sponsible for the attenuated response.
Mouse PEFs treated with IL-1, and to a lesser degree
with TNF-a, responded by phosphorylating p38a and pro-
ducing and/or secreting IL-6. Fibroblast IL-6 production
was inhibited by SB-203,580. ES cells, on the other hand,
lacked receptors for IL-1 and TNF-a; IL-1 (or TNF) failed
Table I. ES Cell Viability after Adriamycin-induced Apoptosis
Viability
Adriamycin p38a1/1
p38a1/1 1 
SB-203,580 p38a2/2
p38a2/2 1 
SB-203,580
mg/ml % % % %
0 72 64 68 66
0.05 51 48 43 36
0.16 44 37 30 29
0.50 28 27 22 21
1.50 21 19 17 24
4.50 23 20 17 19
ES cells (2 3 106 cells per well in 6-well cluster plates) were incubated
for 18 h with the indicated concentration of adriamycin. Where
indicated, SB-203,580 was also present at 10 mM. The cells were
subsequently harvested and analyzed by flow cytometry after staining
with FITC-labeled annexin V and propidium iodide. The percentage of
viable cells (those not staining with either annexin V or propidium
iodide) was determined based on 10,000 gated events. Data are
representative of three separate experiments.867 Allen et al.
to promote p38a phosphorylation and to stimulate IL-6
production. However, after wild-type ES cells were sub-
jected to an in vitro differentiation process, a percentage of
the population expressed the type 1 IL-1R. These receptor-
positive cells responded to IL-1 and generated IL-6 via an
SB-203,580–inhibitable process.
p38a2/2 ES cells also gave rise to a population of IL-
1R–positive cells after the in vitro differentiation process.
Based on the percentage of cells that expressed this receptor,
no difference in the efficiency of the differentiation response
to an IL-1R–positive state was observed between p38a1/1
and p38a2/2 cell types. A large number of cytokine and/or
growth factor signaling cascades have been reported to in-
volve p38 (7); for example, SB-203,580 is reported to in-
hibit GM-CSF–induced cell proliferation (63). Moreover,
p38 has been implicated as an important element in cellular
differentiation processes. For example, the terminal differ-
entiation of L8 muscle cells is blocked by SB-203,580 (64).
Therefore, the similar efficiency at which wild-type and
p38a2/2 ES cells differentiated to an IL-1R–positive phe-
notype was somewhat of a surprise. However, the IL-1R–
positive p38a2/2 cells were greatly impaired in their IL-1
responsiveness as judged by a reduction in IL-6 production
relative to wild-type cells.
RT-PCR indicated that wild-type ES cells express all
four p38 kinase family members. Knockout of the p38a al-
lele eliminated expression of p38a mRNA without altering
expression of the other three kinases. Therefore, the gene-
targeting strategy successfully eliminated expression of p38a
individually. Despite loss of just one of the four p38 kinases,
p38a2/2 ES cells, in contrast to their wild-type counter-
parts, did not respond to anisomycin or sodium arsenite to
activate MAPKAP kinase 2, and they did not generate IL-6
in response to IL-1 stimulation after in vitro differentiation.
With respect to these activities (and within the context of
the ES cell), therefore, p38a does not serve a redundant role
to its relatives. The markedly reduced responsiveness of
p38a2/2 ES cells is surprising based on literature reports in-
dicating that MAPKAP kinase 2 is an in vitro substrate for
both p38a and p38b family members (25), and evidence
that IL-1 treatment can promote activation of all p38 para-
logs (23, 25, 26, 59).
p38 kinases have also been implicated as regulators of ap-
optosis. For example, activation of p38 is reported to be re-
quired for apoptosis of PC-12 cells after nerve growth factor
withdrawal (52). Likewise, serum removal from rat-1 fibro-
blasts led to p38 activation and to apoptosis (40). In contrast,
an inhibitor of p38, SB-202,190, is reported to promote ap-
optosis of Jurkat cells (39); overexpression of p38b, but not
p38a, attenuated the SB-202,190 effect, suggesting that the
response was isoform dependent. ES cells demonstrated an
apoptotic response when treated with the chemical inducers
of apoptosis, staurosporin or adriamycin. Two separate indi-
cators of apoptosis, PARP cleavage and annexin V binding,
were observed in ES cells treated with the chemical induc-
ers. Importantly, p38a1/1 and p38a2/2 ES cells were equally
sensitive to the chemical-induced apoptotic response. This
suggests that p38a does not play a dominant role in this
form of ES cell apoptosis. Moreover, the ES cell apoptotic
response was not affected by SB-203,580, suggesting that
other CSAID-sensitive proteins also were not involved in
the death response.
The ability of CSAIDs to modulate inflammatory cyto-
kine production by monocytes and macrophages highlights
p38 as an attractive pharmaceutical target. Human mono-
cytes were recently reported to express both p38a and p38d,
and macrophages derived from in vitro differentiation of
blood monocytes continued to express both of these kinases
(26). In contrast, p38b and p38g were not expressed in the
monocytes and/or macrophages (26). When macrophages
were stimulated with LPS, a large increase in p38a activity
was observed, with only a modest activation of p38d (26).
Therefore, from the standpoint of regulating monocyte
and/or macrophage inflammatory function, it appears that
p38a is the key p38 kinase. The data presented in this re-
port using in vitro–differentiated ES cells clearly support
p38a serving as a key mediator of IL-1 signal transduction.
IL-1R–positive p38a1/1 cells responded to IL-1 and gener-
ated IL-6. In contrast, p382/2 IL-1R–positive cells gener-
ated minimal quantities of IL-6. IL-1, therefore, appears
similar to LPS in its utilization of p38a to achieve target cell
activation.
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